Legislator Jurisprudence & Législation
DE FR IT EN
Analyser dans Legislator
3 B 27/14, 3 B 27/14 (3 C 15/15) ECLI:DE:BVerwG:2015:060715B3B27.14.0 Généré par l'IA

Preconditions for refusing extension of pharmaceutical marketing authorization based on unfavorable benefit-risk profile

Numéro de cause 3 B 27/14, 3 B 27/14 (3 C 15/15)
Autorité / Tribunal
Juridiction Allemagne (DE)
Date de la décision
Issue du litige Admis (Allowed)
Ouvrir la source officielle Version Markdown lisible par machine (.md)

Synthèse Legislator

Généré par l'IA

The Federal Administrative Court (BVerwG) granted the appellant's complaint and allowed the appeal for reasons of fundamental significance, thereby remitting the case for further review. The dispute concerns the prerequisites for the refusal to extend a pharmaceutical marketing authorization on the basis of an unfavorable benefit-risk profile. The decisive legal basis involves the interpretation and application of § 31 Abs. 3 in conjunction with § 25 Abs. 2 Satz 1 Nr. 5 of the German Pharmaceutical Act (AMG), which governs the conditions under which a medicine's authorization can be denied extension due to safety or efficacy concerns.

Regeste Legislator

Généré par l'IA

§ 132 Abs. 2 Nr. 1 VwGO, § 63 Abs. 1 Satz 1 GKG, § 47 Abs. 1 GKG, § 52 Abs. 1 GKG; Preconditions for refusing extension of pharmaceutical marketing authorization based on unfavorable benefit-risk profile: The dispute concerns the prerequisites for the refusal to extend a pharmaceutical marketing authorization on the basis of an unfavorable benefit-risk profile. The decisive legal basis involves the interpretation and application of § 31 Abs. 3 in conjunction with § 25 Abs. 2 Satz 1 Nr. 5 of the German Pharmaceutical Act (AMG), which governs the conditions under which a medicine's authorization can be denied extension due to safety or efficacy concerns.

Mots-clés

Généré par l'IA
profits et risques réclamation administrative motifs de sécurité motif de révision juste motif pour le non-usage médicaments

Dispositions légales citées

Généré par l'IA
§ 132 Abs. 2 Nr. 1 VwGO
Cited as the legal basis for granting leave to appeal on grounds of fundamental significance in the operative order.
§ 63 Abs. 1 Satz 1 GKG
Cited in the dispositive for the preliminary determination of the amount in dispute for costs.
§ 47 Abs. 1 GKG
Cited in the dispositive for the preliminary determination of the amount in dispute for costs.
§ 52 Abs. 1 GKG
Cited in the dispositive for the preliminary determination of the amount in dispute for costs.
Généré par l'IA
3 B 26/14, 3 B 26/14 (3 C 14/15)
Conditions for refusing renewal of pharmaceutical license based on unfavorable benefit-risk ratio under German Medicines Act
3 B 63/12, 3 B 63/12 (3 C 10/13)
Pharmaceutical authorization denial: Clarifying prerequisites for rejecting combination product justification under § 25 AMG
3 B 69/16, 3 B 69/16 (3 C 4/18)
Standing to challenge exemption of pharmacist-manufactured drug from marketing authorization under § 42(2) VwGO and § 21 AMG
3 C 19/09
Medicinal product license: Impossibility of imposing substantive contraindications via information-text conditions under § 28 AMG
3 C 15/15
Extension of marketing authorization for homeopathic drug: burden of proof for lack of efficacy and benefit-risk assessment in renewal proceedings

Questions juridiques clés extraites par Legislator

Généré par l'IA
§ 132 Abs. 2 Nr. 1 VwGO

Cited as the legal basis for granting leave to appeal on grounds of fundamental significance in the operative order.

§ 47 Abs. 1 GKG

Cited in the dispositive for the preliminary determination of the amount in dispute for costs.

§ 52 Abs. 1 GKG

Cited in the dispositive for the preliminary determination of the amount in dispute for costs.

§ 63 Abs. 1 Satz 1 GKG

Cited in the dispositive for the preliminary determination of the amount in dispute for costs.

Vous souhaitez savoir comment cet arrêt s'applique à votre dossier ?

Analysez cette décision avec la législation fédérale, le droit cantonal, la doctrine et la jurisprudence subséquente dans Legislator AI.

Ouvrir dans Legislator →

Texte complet

Revisionszulassung; Voraussetzungen für eine Versagung der Verlängerung einer Arzneimittelzulassung

[GRUENDE]

Die Beschwerde hat Erfolg. Der Rechtssache kommt die geltend gemachte grundsätzliche Bedeutung (§ 132 Abs. 2 Nr. 1 VwGO) zu. Sie wird dem Bundesverwaltungsgericht voraussichtlich Gelegenheit zur Klärung der Voraussetzungen für die Versagung der Verlängerung einer Arzneimittelzulassung nach § 31 Abs. 3 i.V.m. § 25 Abs. 2 Satz 1 Nr. 5 AMG (ungünstiges Nutzen-Risiko-Verhältnis) geben.

Die vorläufige Streitwertfestsetzung für das Revisionsverfahren beruht auf § 47 Abs. 1, § 52 Abs. 1 und § 63 Abs. 1 Satz 1 GKG.